Attached files
| file | filename |
|---|---|
| EX-5.1 - EXHIBIT 5.1 - IMMUNE PHARMACEUTICALS INC | v471770_ex5-1.htm |
| S-1/A - S-1/A - IMMUNE PHARMACEUTICALS INC | v471770_s1a.htm |
Exhibit 23.1
Immune Pharmaceuticals, Inc.
New York, New York
We hereby consent to the use in the Prospectus constituting a part of this Registration Statement of our report dated May 17, 2017, relating to the consolidated financial statements of Immune Pharmaceuticals, Inc., which is incorporated by reference in that Prospectus. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
We also consent to the reference to us under the caption “Experts” in the Prospectus.
| /S/ BDO USA, LLP | |
| New York, New York |
July 18, 2017